MDWD Nasdaq Medicinal Chemicals & Botanical Products Financials FY2016βFY2025
MediWound Ltd. had $17.0M of revenue in fiscal 2025, down 16.1% on the year before. Over five years, revenue changed β4.9% a year on average.
Hi! I read MediWound Ltd.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
β16.1%
No. Sales fell 16.1% last year.
Does it make a profit?
β140.8%
No. It lost money last year.
Does profit turn into cash?
β127.5%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 8
Mixed. It passes 4 of 8 health tests.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days MediWound Ltd. did it, and the next one. Share prices often move a lot on those days.
Next results
November 19, 2026
Thursday Β· in 24 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Mar 5, 2026 | Period ended Dec 31, 2025 | Before the market opens | 20-F β |
| Mar 19, 2025 | Period ended Dec 31, 2024 | Before the market opens | 20-F β |
| Mar 21, 2024 | Period ended Dec 31, 2023 | Before the market opens | 20-F β |
| Mar 16, 2023 | Period ended Dec 31, 2022 | Before the market opens | 20-F β |
| Mar 17, 2022 | Period ended Dec 31, 2021 | Before the market opens | 20-F β |
| Feb 25, 2021 | Period ended Dec 31, 2020 | Before the market opens | 20-F β |
| Feb 25, 2020 | Period ended Dec 31, 2019 | Before the market opens | 20-F β |
| Mar 25, 2019 | Period ended Dec 31, 2018 | Before the market opens | 20-F β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· MediWound Ltd. had $17.0M of revenue in fiscal 2025, down 16.1% on the year before. Over five years, revenue changed β4.9% a year on average. Its operating margin was β149.0%, down 53.0Β pts: of every 100 in sales, about β149 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· MediWound Ltd. lost $23.9M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$21.6M in fiscal 2025, β127.5% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· In the last 12 months, insiders bought $0.1M and sold $0.1M of shares on the open market.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.1M
3 insiders
Sold, 12 months
$0.1M
2 insiders
Of sales under plans
0%
$0.0M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 1, 2026 | Samuel RubinsteinDirector | Bought | 525 | $12.62 | $0.0M | Form 4 |
| Sep 1, 2026 | Samuel RubinsteinDirector | Sold | 525 | $12.72 | $0.0M | Form 4 |
| Aug 27, 2026 | Shmuel HessCOO & Chief Commercial Officer | Sold | 3,958 | $12.93 | $0.1M | Form 4 |
| Aug 26, 2026 | Shmuel HessCOO & Chief Commercial Officer | Sold | 1,865 | $13.00 | $0.0M | Form 4 |
| Jun 3, 2026 | Nachum ShamirDirector | Bought | 6,000 | $14.00 | $0.1M | Form 4 |
| Jun 1, 2026 | David Morton FoxDirector | Bought | 3,537 | $14.11 | $0.0M | Form 4 |
| May 29, 2026 | Samuel RubinsteinDirector | Bought | 150 | $14.33 | $0.0M | Form 4 |
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably MediWound Ltd. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $11.0M | $33.9M | $11.9M | $9.2M | $4.8M |
| Interest coverage | β4.8x | β0.7x | β8.1x | β1.5x | β10.3x |
| Current ratio | 1.4x | 3.8x | 2.7x | 2.0x | 2.3x |
| Quick ratio | 1.3x | 3.6x | 2.6x | 1.9x | 2.2x |
| Total assets | $19.7M | $50.0M | $66.5M | $73.5M | $86.3M |
| Total liabilities | $24.3M | $39.1M | $34.9M | $42.3M | $42.6M |
| Shareholders' equity | β$4.6M | $10.9M | $31.6M | $31.2M | $43.6M |
| Net debt (β = net cash) | β | β | β | β | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· MediWound Ltd. passes 4 of 8 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 5 / 8 | 3 / 8 | 6 / 8 | 1 / 8 | 4 / 8 | 4 / 8 | 1 / 8 | 1 / 8 | 4 / 8 |
| Accruals ratio | β6.8% | β14.3% | 27.9% | β8.8% | β6.4% | β18.2% | β22.1% | 6.4% | β23.7% | β9.7% |
| Altman Z'' | β8.09 | β6.00 | β7.30 | β4.65 | β11.97 | β27.13 | β7.35 | β6.05 | β7.81 | β6.94 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $1.6M | $2.5M | $3.4M | $31.8M | $21.8M | $23.8M | $26.5M | $18.7M | $20.2M | $17.0M |
| Gross profit | β$0.6M | $0.9M | $1.3M | $19.9M | $7.5M | $8.8M | $13.2M | $3.6M | $2.6M | $3.3M |
| Research and development | $7.1M | $5.5M | $4.1M | $5.0M | $7.7M | $10.3M | $10.2M | $7.5M | $8.9M | $14.3M |
| Operating income | β$20.2M | β$13.7M | β$4.0M | $4.5M | β$8.8M | β$11.2M | β$8.3M | β$15.3M | β$19.4M | β$25.3M |
| Interest expense | $0.9M | $1.3M | $2.1M | $3.0M | $1.3M | $2.3M | $11.6M | $1.9M | $12.8M | $2.5M |
| Pretax income | β | β | β | $2.1M | β$9.3M | β$13.5M | β$19.5M | β$6.5M | β$30.2M | β$23.7M |
| Income tax | β | β | β | $0.0M | $0.0M | $0.0M | $0.1M | $0.2M | $0.1M | $0.2M |
| Net income | β$18.9M | β$22.1M | β$1.1M | $5.0M | β$9.2M | β$13.6M | β$19.6M | β$6.7M | β$30.2M | β$23.9M |
| Diluted EPS | β$0.86 | β$0.95 | β$0.04 | $0.18 | β$2.38 | β$3.48 | β$3.93 | β$0.75 | β$3.03 | β$2.10 |
| Diluted shares | 0.02B | 0.02B | 0.03B | 0.03B | 0.03B | 0.00B | 0.00B | 0.01B | 0.01B | 0.01B |
| Cash flow | ||||||||||
| Cash from operations | β$16.4M | β$16.5M | β$12.2M | $8.3M | β$6.9M | β$8.9M | β$11.9M | β$10.5M | β$13.6M | β$16.1M |
| Capital expenditure | $0.7M | $1.0M | $0.5M | $0.8M | $0.9M | $0.5M | $0.6M | $6.5M | $6.3M | $5.5M |
| Free cash flow | β$17.1M | β$17.5M | β$12.7M | $7.5M | β$7.8M | β$9.4M | β$12.4M | β$16.9M | β$19.9M | β$21.6M |
| Depreciation and amortization | $0.5M | $0.5M | $0.5M | $0.5M | $0.4M | $0.6M | $0.4M | $0.7M | $0.6M | $0.6M |
| Stock-based compensation | $3.2M | $1.4M | $0.6M | $1.2M | $1.3M | $1.7M | $1.9M | $1.9M | $3.1M | $3.1M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $28.9M | $36.1M | $6.7M | $7.2M | $17.4M | $11.0M | $33.9M | $11.9M | $9.2M | $4.8M |
| Current assets | $33.6M | $41.5M | $32.7M | $35.6M | $26.2M | $15.0M | $45.8M | $49.7M | $52.2M | $60.0M |
| Current liabilities | $5.4M | $5.4M | $4.9M | $10.4M | $8.3M | $10.7M | $12.1M | $18.1M | $26.5M | $25.7M |
| Inventory | $0.8M | $1.9M | $1.7M | $1.6M | $1.4M | $1.2M | $2.0M | $2.8M | $2.7M | $4.1M |
| Property and equipment, net | $1.3M | $1.9M | $2.0M | $2.3M | $2.6M | $2.5M | $2.4M | $9.2M | $14.1M | $18.6M |
| Intangible assets | $0.8M | $0.6M | $0.5M | $0.4M | $0.4M | $0.3M | $0.2M | $0.2M | $0.1M | $0.0M |
| Total assets | $35.8M | $44.1M | $35.3M | $40.6M | $31.1M | $19.7M | $50.0M | $66.5M | $73.5M | $86.3M |
| Total liabilities | $28.0M | $34.8M | $26.3M | $25.4M | $23.8M | $24.3M | $39.1M | $34.9M | $42.3M | $42.6M |
| Shareholders' equity | $7.8M | $9.4M | $9.0M | $15.2M | $7.3M | β$4.6M | $10.9M | $31.6M | $31.2M | $43.6M |
| Margins | ||||||||||
| Gross margin | β38.5% | 36.8% | 38.6% | 62.7% | 34.7% | 36.9% | 49.7% | 19.1% | 13.0% | 19.2% |
| Operating margin | β1,293.6% | β548.4% | β116.4% | 14.1% | β40.6% | β47.2% | β31.5% | β81.8% | β95.9% | β149.0% |
| EBITDA margin | β1,263.2% | β530.0% | β102.5% | 15.7% | β38.8% | β44.9% | β29.9% | β78.2% | β92.8% | β145.5% |
| Net margin | β1,212.1% | β887.4% | β31.1% | 15.6% | β42.3% | β57.0% | β74.0% | β35.9% | β149.5% | β140.8% |
| FCF margin | β1,098.6% | β701.1% | β372.7% | 23.6% | β35.9% | β39.6% | β47.0% | β90.6% | β98.4% | β127.5% |
| Returns | ||||||||||
| Return on capital employed | β66.3% | β35.4% | β13.0% | 14.9% | β38.8% | β124.4% | β22.0% | β31.6% | β41.3% | β41.7% |
| Return on equity | β243.1% | β258.4% | β11.5% | 41.1% | β82.0% | β1,007.5% | β619.0% | β31.6% | β96.3% | β63.9% |
| Return on assets | β52.8% | β55.4% | β2.7% | 13.1% | β25.7% | β53.3% | β56.2% | β11.5% | β43.2% | β29.9% |
| Return on tangible equity | β269.9% | β253.5% | β12.5% | 33.6% | β133.1% | β | β183.5% | β21.4% | β97.3% | β54.8% |
| Growth | ||||||||||
| Revenue growth | β | 60.2% | 36.3% | 834.7% | β31.5% | 9.2% | 11.5% | β29.5% | 8.2% | β16.1% |
| Net income growth | β | β | β | β | β285.6% | β | β | β | β | β |
| EPS growth | β | β | β | β | β1,422.2% | β | β | β | β | β |
| FCF growth | β | β | β | β | β204.3% | β | β | β | β | β |
| Share count change | β | 6.8% | 16.2% | 0.2% | 0.1% | β85.7% | 28.1% | 80.7% | 10.5% | 14.2% |
| Financial health | ||||||||||
| Interest coverage | β22.5x | β10.9x | β1.9x | 1.5x | β6.9x | β4.8x | β0.7x | β8.1x | β1.5x | β10.3x |
| Current ratio | 6.2x | 7.6x | 6.7x | 3.4x | 3.2x | 1.4x | 3.8x | 2.7x | 2.0x | 2.3x |
| Quick ratio | 6.1x | 7.3x | 6.3x | 3.3x | 3.0x | 1.3x | 3.6x | 2.6x | 1.9x | 2.2x |
| Capital allocation | ||||||||||
| Capex / revenue | 43.1% | 41.9% | 15.3% | 2.5% | 4.2% | 2.1% | 2.1% | 34.6% | 31.0% | 32.5% |
| Stock comp / revenue | 203.5% | 54.6% | 19.0% | 3.9% | 6.1% | 7.0% | 7.3% | 10.4% | 15.5% | 18.3% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 5.0 | 3.0 | 6.0 | 1.0 | 4.0 | 4.0 | 1.0 | 1.0 | 4.0 |
| Altman Z'' | β8.1 | β6.0 | β7.3 | β4.6 | β12.0 | β27.1 | β7.4 | β6.1 | β7.8 | β6.9 |
| Accruals ratio | β6.8% | β14.3% | 27.9% | β8.8% | β6.4% | β18.2% | β22.1% | 6.4% | β23.7% | β9.7% |
Source: SEC EDGAR XBRL filings (CIK 0001593984). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
